Condition: Very High Risk Acute Lymphoblastic Leukemia · CD19 CAR-T Therapy · Sponsor: Seoul National University Hospital
This is a phase 2 clinical trial targeting pediatric and adolescent patients diagnosed with CD19-positive B-ALL, considered very high-risk group. The study aims to administer CD19 CAR-T therapy as an alternative to hematopoietic stem cell transplantation in patients eligible for such transplantation. The trial includes patients aged 25 or younger.
This description comes directly from the study's public registry record.
Hyoung Jin Kang, Professor · 02-2072-3452 · kanghj@snu.ac.kr
Always discuss trial participation with your own doctor first.
| Seoul National University Children's Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06247501